Materias dentro de su búsqueda.
Mostrando 1,521 - 1,540 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.23s Limitar resultados
  1. 1521
    “…The utilization of trastuzumab biosimilar medications is of particular interest in HER2-positive breast cancer as these drugs have the potential for cost savings and increased utilization/access to HER2 targeted therapy in both early stage and metastatic HER2-positive breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States
  2. 1522
    “…Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The emerging role of CDK4/6i in HER2-positive breast cancer
  3. 1523
    por Ditsch, Nina, Schmidt, Marcus
    Publicado 2019
    “…The article gives an overview of current treatment options for metastatic hormone receptor-positive and HER2-negative breast cancer. The focus is on combined therapies, e.g., with CDK4/6 inhibition compared with purely endocrine-based therapies in the pre- and postmenopause, presenting the latest study results. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
  4. 1524
    “…The three ADCs showed good binding to HER2 and in vitro cytotoxicity, which validate the TBM structure as an attractive alternative scaffold for rebridging bioconjugation.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
  5. 1525
    “…Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
  6. 1526
    “…The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
  7. 1527
    “…Although the positivity of human epidermal growth factor receptor 2 (HER2) is low in colorectal cancer (CRC), anti-HER2 is becoming a new target therapy in metastatic colorectal cancer (mCRC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer
  8. 1528
    “…Here, we investigated the genetic differences between HER2‐positive and HER2‐negative admixed breast cancer components. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
  9. 1529
    “…Human epidermal growth factor receptor-2 (HER2)-expression gastro-oesophageal adenocarcinomas (GEA) gained interest as an important target for therapy with trastuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies
  10. 1530
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
  11. 1531
    “…INTRODUCTION: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
  12. 1532
    “…RESULTS: In a cohort of 869 consecutive early HR-positive, HER-negative breast cancer patients, EPclin was utilized in 156 (18.0%) patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
  13. 1533
    “…INTRODUCTION: Phytolacca dodecandra L’Hér. is a native plant of sub-Saharan Africa and Madagascar which is traditionally used for various ailments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacology, Phytochemistry, and Toxicity Profiles of Phytolacca dodecandra L’Hér: A Scoping Review
  14. 1534
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro
  15. 1535
    “…HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
  16. 1536
    “…The highest level of MALAT1 was observed in metastatic triple-negative breast cancer and trastuzumab-resistant HER2 (human epidermal growth factor receptor 2) overexpressing (HER2+) cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
  17. 1537
    “…BACKGROUND: Deregulation of HER2 expression could affect the biological characteristics of gastric cancer cells and treatment option for gastric cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells
  18. 1538
    “…Circ-HER2/HER2–103 positive TNBC patients harbored worse overall prognosis than circ-HER2/HER2–103 negative patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
  19. 1539
    “…CD47 is upregulated preferentially in HER2-expressing cells, and blocking CD47 or HER2 reduces both receptors with diminished clonogenicity and augmented phagocytosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
  20. 1540
    “…[Image: see text] Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with more frequent cancer recurrence and metastasis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Red-Fluorescent Pt Nanoclusters for Detecting and Imaging HER2 in Breast Cancer Cells
Herramientas de búsqueda: RSS